SCHEMBL7845227

SCHEMBL7845227

COC(=O)c1cccc(-c2cccc(OCCCCCCN)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.44
MTNR1B P49286 2/20 0.44
LTB4R Q15722 1/20 0.43
GAA P10253 2/20 0.43
CYP1A2 P05177 1/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CNR2 P34972 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
DHODH Q02127 1/20 0.42
CES1 P23141 3/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
FAAH O00519 1/20 0.42
CTSA P10619 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL847470 0.99 MTNR1A (0.43) MTNR1AMTNR1BLTB4RGAACYP1A2
SCHEMBL846739 0.90 LTB4R (0.43) LTB4RGAACYP1A2MAPTRECQL
SCHEMBL861993 0.87 LTB4R (0.41) LTB4RGAACYP1A2MAPTRECQL
SCHEMBL846487 0.84 CTSA (0.40) LTB4RGAACYP1A2MAPTRECQL
SCHEMBL7848484 0.83 HDAC1 (0.45) LTB4RCNR2HDAC1HDAC2CES1
SCHEMBL847238 0.81 SUCNR1 (0.60) MTNR1AMTNR1BCNR2
SCHEMBL846498 0.79 MEN1 (0.49) ALDH1A1CNR2HDAC1HDAC2CES1
SCHEMBL22940145 0.78 PLA2G2A (0.55) CYP1A2MAPTLMNASMN1; SMN2
SCHEMBL847234 0.77 SMPD1 (0.53) GAAMAPTKDM4EALDH1A1LMNA
SCHEMBL25003937 0.76 PLA2G2A (0.58) CYP1A2MAPTKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120141414-A1 Bimacrocylic HCV NS3 Protease Inhibitors SEQUOIA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120141414-A1 Bimacrocylic HCV NS3 Protease Inhibitors SEQUOIA PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2010135748-A1 BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS SEQUOIA PHARMACEUTICALS INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120141414-A1 Bimacrocylic HCV NS3 Protease Inhibitors HAVCR2, CTRC, CTSC MTNR1A 3665/4885MTNR1B 3075/4885LTB4R 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.